Lisa Wells Roark

Lisa Wells Roark serves as a key procurement lead within the U.S. Army’s Medical Research Acquisition Activity (W81XWH), driving the acquisition of advanced biomedical research and diagnostic capabilities critical to warfighter health and operational readiness. She manages complex research and development contracts focused on translating laboratory innovations into field-deployable medical solutions, including molecular diagnostics, biodefense countermeasures, and clinical analytics platforms. Her role is central to the agency’s mission of accelerating the transition of life sciences breakthroughs from concept to combat support, ensuring that cutting-edge medical technologies meet the rigorous demands of military operational environments. Her contractor relationships are primarily with specialized biomedical research firms, biotechnology innovators, and contract research organizations with deep expertise in translational medicine and military-relevant health technologies. While no specific vendors are identified in current records, her procurement patterns suggest consistent engagement with firms possessing advanced capabilities in genomics, point-of-care diagnostics, and bioinformatics systems. She favors partners with proven experience in federal research programs and a demonstrated ability to deliver under stringent regulatory and security requirements. Lisa’s contracting activity shows a 100% preference for open competition with no set-asides, indicating a strategic focus on technical excellence and mission-critical capability over socioeconomic classifications. This reflects the high-stakes nature of medical R&D acquisitions where specialized expertise and rapid innovation outweigh traditional small business participation mandates. Her procurement focus is exclusively under NAICS 511210—Software Publishers, specifically those developing custom biomedical software, data analytics platforms, and AI-driven diagnostic tools. She consistently seeks vendors with domain expertise in military medicine, clinical trial management systems, and real-time health monitoring technologies, ensuring acquisitions align with the Army’s next-generation medical readiness objectives.